Court Place Advisors LLC Sells 400 Shares of Johnson & Johnson (NYSE:JNJ)

Court Place Advisors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 12,275 shares of the company’s stock after selling 400 shares during the period. Court Place Advisors LLC’s holdings in Johnson & Johnson were worth $1,989,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Santori & Peters Inc. acquired a new stake in shares of Johnson & Johnson during the third quarter worth $211,000. Canal Capital Management LLC grew its position in shares of Johnson & Johnson by 5.6% during the 3rd quarter. Canal Capital Management LLC now owns 47,355 shares of the company’s stock worth $7,674,000 after buying an additional 2,511 shares during the period. Blackston Financial Advisory Group LLC increased its stake in shares of Johnson & Johnson by 10.8% in the 3rd quarter. Blackston Financial Advisory Group LLC now owns 4,737 shares of the company’s stock valued at $768,000 after acquiring an additional 462 shares during the last quarter. Ballentine Partners LLC raised its position in shares of Johnson & Johnson by 8.2% in the 3rd quarter. Ballentine Partners LLC now owns 56,392 shares of the company’s stock valued at $9,139,000 after acquiring an additional 4,273 shares during the period. Finally, Coerente Capital Management boosted its stake in Johnson & Johnson by 1.9% during the 3rd quarter. Coerente Capital Management now owns 156,367 shares of the company’s stock worth $25,341,000 after acquiring an additional 2,959 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 1.7 %

Johnson & Johnson stock opened at $160.88 on Friday. The company has a fifty day simple moving average of $163.41 and a 200 day simple moving average of $155.07. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $387.28 billion, a P/E ratio of 23.28, a price-to-earnings-growth ratio of 2.90 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the previous year, the business earned $2.66 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Royal Bank of Canada increased their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Morgan Stanley increased their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, TD Securities dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.